Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb;30(1):119-33.
doi: 10.1016/j.hoc.2015.09.005. Epub 2015 Oct 23.

Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors

Nitya Raj  1 , Diane Reidy-Lagunes  2
Affiliations
Review

Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors

Nitya Raj et al. Hematol Oncol Clin North Am. 2016 Feb.

Abstract

Pancreatic neuroendocrine tumors are an uncommon tumor type and compose 1% to 2% of all pancreatic neoplasms. They are rarely localized at presentation and are typically diagnosed in the presence of metastatic disease. The management poses a significant challenge because of the heterogeneous clinical presentations and varying degrees of aggressiveness. A variety of systemic therapies have been developed for the management of pancreatic neuroendocrine tumors, including somatostatin analogues, a select group of cytotoxic chemotherapy agents, and targeted or biological agents. This article reviews the available systemic therapy options for advanced pancreatic neuroendocrine tumors.

Keywords: Carcinoid tumors; Everolimus; Lanreotide; Neuroendocrine tumors; Octreotide; Pancreatic neuroendocrine tumors; Sunitinib.

PubMed Disclaimer

References

    1. Kunz PL, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557–77. - PMC - PubMed
    1. Moertel CG, et al. Treatment of Neuroendocrine Carcinomas with Combined Etoposide and Cisplatin - Evidence of Major Therapeutic Activity in the Anaplastic Variants of These Neoplasms. Cancer. 1991;68(2):227–232. - PubMed
    1. Modlin IM, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncology. 2008;9(1):61–72. - PubMed
    1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–959. - PubMed
    1. Dumlu EG, Karakoc D, Ozdemir A. Nonfunctional Pancreatic Neuroendocrine Tumors: Advances in Diagnosis, Management and Controversies. Int Surg. 2015 - PMC - PubMed

MeSH terms